Kessels R, May A, Koopman M, Roes K
BMC Med Res Methodol. 2023; 23(1):117.
PMID: 37179306
PMC: 10183126.
DOI: 10.1186/s12874-023-01941-5.
Teunissen F, Willigenburg T, Meijer R, van Melick H, Verkooijen H, van der Voort van Zyp J
World J Urol. 2022; 40(9):2205-2212.
PMID: 35861861
PMC: 9427931.
DOI: 10.1007/s00345-022-04092-2.
Zhang X, Yang D, Wang C, Huang L
Transl Cancer Res. 2022; 10(10):4316-4326.
PMID: 35116290
PMC: 8797335.
DOI: 10.21037/tcr-21-1189.
Mendis S, Anand S, Karasinska J, Dasari A, Unger J, Gothwal A
Oncologist. 2020; 26(2):107-114.
PMID: 32960478
PMC: 7873318.
DOI: 10.1002/onco.13534.
Nipp R, Lee H, Gorton E, Lichtenstein M, Kuchukhidze S, Park E
Oncologist. 2019; 24(8):1048-1055.
PMID: 30988039
PMC: 6693715.
DOI: 10.1634/theoncologist.2019-0146.
Commentary: considerations for using the 'Trials within Cohorts' design in a clinical trial of an investigational medicinal product.
Bibby A, Torgerson D, Leach S, Lewis-White H, Maskell N
Trials. 2018; 19(1):18.
PMID: 29310706
PMC: 5759253.
DOI: 10.1186/s13063-017-2432-3.
Institutional Scientific Review of Cancer Clinical Research Protocols: A Unique Requirement That Affects Activation Timelines.
Ning N, Yan J, Dietrich M, Xie X, Gerber D
J Oncol Pract. 2017; 13(12):e982-e991.
PMID: 29019706
PMC: 5728362.
DOI: 10.1200/JOP.2017.024299.
Video intervention increases participation of black breast cancer patients in therapeutic trials.
Robinson B, Newman A, Tefera E, Herbolsheimer P, Nunes R, Gallagher C
NPJ Breast Cancer. 2017; 3:36.
PMID: 28944289
PMC: 5603544.
DOI: 10.1038/s41523-017-0039-1.
The Utrecht cohort for Multiple BREast cancer intervention studies and Long-term evaLuAtion (UMBRELLA): objectives, design, and baseline results.
Young-Afat D, van Gils C, van den Bongard H, Verkooijen H
Breast Cancer Res Treat. 2017; 164(2):445-450.
PMID: 28444532
PMC: 5487711.
DOI: 10.1007/s10549-017-4242-4.
R-IDEAL: A Framework for Systematic Clinical Evaluation of Technical Innovations in Radiation Oncology.
Verkooijen H, Kerkmeijer L, Fuller C, Huddart R, Faivre-Finn C, Verheij M
Front Oncol. 2017; 7:59.
PMID: 28421162
PMC: 5378068.
DOI: 10.3389/fonc.2017.00059.
Patient Navigation As a Model to Increase Participation of African Americans in Cancer Clinical Trials.
Fouad M, Acemgil A, Bae S, Forero A, Lisovicz N, Martin M
J Oncol Pract. 2016; 12(6):556-63.
PMID: 27189356
PMC: 4957258.
DOI: 10.1200/JOP.2015.008946.
Financial Burden of Cancer Clinical Trial Participation and the Impact of a Cancer Care Equity Program.
Nipp R, Lee H, Powell E, Birrer N, Poles E, Finkelstein D
Oncologist. 2016; 21(4):467-74.
PMID: 26975867
PMC: 4828126.
DOI: 10.1634/theoncologist.2015-0481.
Recognizing the Financial Burden of Cancer Patients in Clinical Trials.
Nipp R, Powell E, Chabner B, Moy B
Oncologist. 2015; 20(6):572-5.
PMID: 25986245
PMC: 4571792.
DOI: 10.1634/theoncologist.2015-0068.
An overview of EMPaCT and fundamental issues affecting minority participation in cancer clinical trials: enhancing minority participation in clinical trials (EMPaCT): laying the groundwork for improving minority clinical trial accrual.
Vickers S, Fouad M
Cancer. 2014; 120 Suppl 7:1087-90.
PMID: 24643645
PMC: 4133979.
DOI: 10.1002/cncr.28569.
Effect of medical oncologists' attitudes on accrual to clinical trials in a community setting.
Somkin C, Ackerson L, Husson G, Gomez V, Kolevska T, Goldstein D
J Oncol Pract. 2013; 9(6):e275-83.
PMID: 24151327
PMC: 5706122.
DOI: 10.1200/JOP.2013.001120.
Enrollment of patients with lung and colorectal cancers onto clinical trials.
Fouad M, Lee J, Catalano P, Vogt T, Zafar S, West D
J Oncol Pract. 2013; 9(2):e40-7.
PMID: 23814523
PMC: 3595449.
DOI: 10.1200/JOP.2012.000598.
Effort required in eligibility screening for clinical trials.
Penberthy L, Dahman B, Petkov V, DeShazo J
J Oncol Pract. 2013; 8(6):365-70.
PMID: 23598846
PMC: 3500483.
DOI: 10.1200/JOP.2012.000646.
Advancing precision medicine for prostate cancer through genomics.
Roychowdhury S, Chinnaiyan A
J Clin Oncol. 2013; 31(15):1866-73.
PMID: 23589550
PMC: 3808235.
DOI: 10.1200/JCO.2012.45.3662.
Barriers to therapeutic clinical trials enrollment: differences between African-American and white cancer patients identified at the time of eligibility assessment.
Penberthy L, Brown R, Wilson-Genderson M, Dahman B, Ginder G, Siminoff L
Clin Trials. 2012; 9(6):788-97.
PMID: 23033547
PMC: 4836611.
DOI: 10.1177/1740774512458992.
Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin.
Tanimoto T, Tsubokura M, Mori J, Pietrek M, Ono S, Kami M
Invest New Drugs. 2012; 31(2):473-8.
PMID: 22965890
DOI: 10.1007/s10637-012-9877-8.
